Browse the evidence

SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce cardiovascular death, heart failure hospitalizations, and renal composite outcomes in patients with type 2 diabetes and chronic kidney disease, regardless of baseline glycemic control.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors like empagliflozin or dapagliflozin. These medications are proven to significantly lower your risk of heart failure, kidney failure, and death, offering protection beyond just blood sugar control.

GLP-1 receptor agonists (liraglutide, semaglutide) reduce major adverse cardiovascular events (MACE) and nephropathy progression in high-risk patients with Type 2 Diabetes.

For those with Type 2 Diabetes and high heart risk, GLP-1 agonists like liraglutide or semaglutide offer strong protection against heart attacks and strokes, as well as kidney damage. Discuss these options with your doctor, especially if you are overweight.

SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) significantly reduce cardiovascular mortality and heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.

If you have Type 2 Diabetes and heart disease or high risk, ask your doctor about SGLT-2 inhibitors (like empagliflozin or dapagliflozin). These drugs protect your heart and kidneys beyond just lowering blood sugar, significantly reducing the risk of heart failure hospitalization and death. Be aware of potential side effects like infections, but discuss how the heart benefits may outweigh these risks for your specific health profile.

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) reduce Major Adverse Cardiovascular Events (MACE) and all-cause mortality in patients with Type 2 Diabetes and established CVD, primarily through weight loss, blood pressure reduction, and anti-inflammatory effects.

If you have Type 2 Diabetes and heart disease, GLP-1 agonists (like semaglutide or liraglutide) are highly effective at reducing the risk of heart attacks, strokes, and death. They work by mimicking a gut hormone to lower blood sugar, promote weight loss, and reduce blood pressure. While they require injections and may cause temporary stomach issues, the heart protection benefits are substantial and well-documented.

Obesity increases the risk of various cancers (e.g., breast, colorectal, liver) through mechanisms involving chronic inflammation, oxidative stress, and altered adipokine secretion (e.g., increased leptin, decreased adiponectin).

Obesity increases your risk for several types of cancer through biological processes like inflammation and hormone imbalance. Maintaining a healthy weight can reduce this risk by mitigating these specific biological factors.

Obesity contributes to cardiovascular disease (CVD) through mechanisms including adipose tissue dysfunction, ectopic fat deposition, and altered adipokine secretion (e.g., increased leptin, decreased adiponectin), leading to hypertension, atherosclerosis, and heart failure.

Obesity increases your risk for heart disease and stroke through biological processes like inflammation and hormone imbalance. Maintaining a healthy weight can reduce this risk by mitigating these specific biological factors.

Discontinuation of semaglutide or tirzepatide leads to significant weight regain, indicating that these therapies require long-term use to maintain metabolic benefits.

If you stop taking semaglutide or tirzepatide, you will likely regain most of the weight you lost. These drugs treat obesity and diabetes as chronic conditions, meaning they are meant to be taken long-term to maintain the health benefits. Stopping them reverses the progress made.

Semaglutide treatment is associated with a significantly higher incidence of gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) compared to placebo, though these are mostly mild to moderate.

Be prepared for gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These are common but usually mild and temporary. Titration helps manage them.

GLP-1 receptor agonists (GLP-1RAs) effectively treat type 2 diabetes and obesity by mimicking endogenous GLP-1 to stimulate glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite via central nervous system signaling.

GLP-1 medications are highly effective for managing type 2 diabetes and obesity. They work by mimicking a natural hormone to boost insulin when needed, lower blood sugar, slow digestion, and reduce hunger. While they often require injections, many are now available as once-weekly shots or even pills. Side effects like nausea are common at first but usually fade. They are not for type 1 diabetes. Always combine with diet and exercise.

Automated insulin delivery (AID) systems significantly improve glycemic control in people with type 1 diabetes by increasing time in range and reducing hypoglycemia compared to other therapies.

If you have Type 1 Diabetes, an Automated Insulin Delivery (AID) system is a highly effective tool to improve your blood sugar control. It automatically adjusts your insulin based on real-time glucose readings, helping you spend more time in your target range and less time in dangerous low or high states. While it still requires you to count carbs and announce meals, the system handles the fine-tuning. Ensure you receive proper training and support from your healthcare provider to get the most benefit and address any access barriers.

Insulin resistance (IR) is a major driver of PCOS pathophysiology, present in 65-95% of women with PCOS, and is independent of and exacerbated by obesity.

Insulin resistance is a core feature of PCOS, affecting most women with the condition, regardless of weight. Managing insulin levels is crucial for treating PCOS symptoms and reducing long-term health risks like type 2 diabetes.

Oral semaglutide (up to 14 mg daily) significantly reduces the risk of major adverse cardiovascular events (MACE) in high-risk patients with type 2 diabetes, specifically those with established atherosclerotic cardiovascular disease or chronic kidney disease.

If you have type 2 diabetes and existing heart disease or kidney issues, taking oral semaglutide (up to 14 mg daily) alongside your standard care significantly lowers your risk of heart attack, stroke, or cardiovascular death compared to a placebo. This benefit is achieved without increasing serious side effects, making it a viable option for cardiovascular risk reduction in this high-risk group.

Tirzepatide does not increase the risk of hypoglycemia compared to placebo and has a lower risk compared to basal insulin.

Unlike insulin, Tirzepatide does not increase the risk of low blood sugar (hypoglycemia) when used alone. In fact, it has a lower risk of causing hypoglycemia compared to basal insulin. This makes it a safer option for patients who are concerned about blood sugar lows.

Once-weekly subcutaneous semaglutide 2.4 mg reduces the risk of major kidney composite endpoints (including macroalbuminuria and persistent eGFR decline) in patients with overweight/obesity and established cardiovascular disease, regardless of diabetes status.

If you have obesity and heart disease but no diabetes, semaglutide 2.4mg weekly offers significant kidney protection. It reduces the risk of serious kidney events like needing dialysis or developing heavy protein in the urine. While there is a temporary initial dip in kidney filtration numbers, long-term outcomes are better than placebo. This is a standard-of-care option for kidney risk reduction in this specific high-risk group.

Semaglutide 2.4 mg slows the rate of eGFR decline and reduces albuminuria (UACR) in patients with overweight/obesity, with greater benefits observed in those with baseline eGFR <60 ml/min/1.73m².

For patients with existing kidney impairment (eGFR <60), semaglutide not only slows further decline but may actually improve eGFR readings compared to placebo. It also significantly reduces albuminuria (protein in urine), a key marker of kidney stress. This benefit is consistent across subgroups.

Tirzepatide treatment is associated with a higher incidence of gastrointestinal adverse events (nausea, diarrhea, vomiting) compared to placebo and insulin, and slightly higher than GLP-1 RAs, though serious adverse events are not significantly different from placebo.

Expect gastrointestinal side effects like nausea, diarrhea, or vomiting, especially when starting or increasing the dose. These are usually mild and go away. Serious side effects (like pancreatitis or heart issues) did not show a statistically significant increase compared to placebo in this analysis. Monitor your symptoms and report severe or persistent issues to your doctor.

Tirzepatide use is associated with a significantly higher incidence of gastrointestinal adverse events, specifically nausea, vomiting, and diarrhea, compared to placebo, although serious adverse event rates remain comparable.

Expect gastrointestinal side effects when starting tirzepatide. Nausea, vomiting, and diarrhea are significantly more common than with a placebo, particularly when starting or increasing the dose. However, these are typically mild to moderate and do not appear to increase the risk of serious health events. Most patients tolerate the medication well enough to continue treatment, which is necessary to achieve the significant weight loss benefits.

Tirzepatide is associated with a higher incidence of gastrointestinal adverse events (nausea, vomiting, constipation, dyspepsia) compared to placebo, which increases with dose and leads to higher discontinuation rates, but does not increase the risk of serious adverse events.

Tirzepatide is more likely to cause stomach issues like nausea and vomiting than a placebo, and these side effects are more common at higher doses. This can lead to some people stopping the medication, but it does not increase the risk of serious health problems. Managing these side effects is key to staying on the treatment.

Tirzepatide use is associated with a significantly higher incidence of adverse reactions, particularly nausea and diarrhea, which are dose-dependent and increase with higher doses (15mg).

Be prepared for potential side effects like nausea and diarrhea when starting Tirzepatide. These side effects are more likely at higher doses (15mg) and may decrease over time as your body adjusts. Most people tolerate the medication well, but it's important to discuss these potential side effects with your doctor.

Tirzepatide use is associated with a significantly increased incidence of adverse reactions, particularly gastrointestinal issues like nausea and diarrhea, which are dose-dependent.

Be prepared for potential side effects when starting Tirzepatide. Nausea and diarrhea are common, especially when you first start or increase the dose. These symptoms often improve over time. Starting at a lower dose (2.5mg) and gradually increasing can help your body adjust. Most people find the side effects manageable.

GLP-1 receptor agonists reduce body weight primarily through central actions that induce satiety, rather than by increasing energy expenditure.

GLP-1 medications help you lose weight by making you feel full, not by boosting your metabolism. New oral versions exist, so you don't necessarily need injections.

Obesity is an independent, chronic non-communicable disease that directly causes cardiovascular disease through pathophysiological mechanisms including insulin resistance, endothelial dysfunction, and inflammation, rather than merely amplifying other risk factors.

Stop viewing obesity as just a lifestyle choice or a minor risk factor. It is a chronic disease with specific biological mechanisms (like inflammation and hormonal imbalance) that directly damage your heart and blood vessels. This means you deserve and need medical treatment, not just willpower-based advice, to manage it effectively and prevent heart disease.

GIP is the predominant incretin hormone in humans responsible for the majority of the incretin effect on postprandial insulin secretion, although its insulinotropic action is impaired in type 2 diabetes due to receptor downregulation.

Your body naturally produces GIP, which is the main hormone helping your pancreas release insulin after eating. In type 2 diabetes, this GIP signal gets weaker because the receptors on your insulin-producing cells become less sensitive. This is why treatments that target both GIP and GLP-1 receptors are often more effective than targeting GLP-1 alone.

In type 2 diabetes, the insulinotropic effect of GIP is significantly reduced or absent, primarily due to hyperglycemia-induced downregulation and degradation of the GIP receptor (GIPR) on beta cells.

In type 2 diabetes, your body still makes GIP, but your insulin cells stop listening to it because high blood sugar damages the receptors. This is reversible: lowering your blood sugar with medication or lifestyle changes can restore your body's natural ability to respond to GIP.